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A B S T R A C T
Since its first discovery in December 2019 in Wuhan, China, COVID-19, caused by the novel coronavirus
SARS-CoV-2, has spread rapidly worldwide. While African countries were relatively spared initially, the
initial low incidence of COVID-19 cases was not sustained for long due to continuing travel links between
China, Europe and Africa. In preparation, Zambia had applied a multisectoral national epidemic disease
surveillance and response system resulting in the identification of the first case within 48 h of the
individual entering the country by air travel from a trip to France. Contact tracing showed that SARS-CoV-
2 infection was contained within the patient’s household, with no further spread to attending health care
workers or community members. Phylogenomic analysis of the patient’s SARS-CoV-2 strain showed that
it belonged to lineage B.1.1., sharing the last common ancestor with SARS-CoV-2 strains recovered from
South Africa. At the African continental level, our analysis showed that B.1 and B.1.1 lineages appear to be
predominant in Africa. Whole genome sequence analysis should be part of all surveillance and case
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detection activities in order to monitor the origin and evolution of SARS-CoV-2 lineages across Africa.
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Introduction
The WHO declared COVID-19, caused by SARS-CoV-2, a Public
Health Emergency of International Concern (PHEIC) on 30 January
2020 and later a pandemic on 11 March 2020 (WHO, 2020a). As of 28
September 2020, there were 32.7 million COVID-19 cases with
991,000 deaths worldwide reported to the WHO (2020b). All African
countries have been affected and have reported a total of 1,172,342
COVID-19 cases, including 25,481 deaths (WHO, 2020b). As the
global COVID-19 events unfolded, and Africa’s first COVID-19 case
was reported from Egypt on 14 February 2020, many African
countries prepared for the arrival of COVID-19 (Kapata et al., 2020).
Zambia embarked on the intensification of the disease surveillance
and emergency preparedness and response systems, including
activating the Public Health Emergency Operations Centre (PHEOC).
As partof preparednessactivities,portsofentrywereputonalertand
thermal scanners were installed for screening incoming passengers
at airports and ground crossing. Key to the preparedness was
ensuring that local and international networks were functional,
including staff training and knowledge exchange, such as among the
Pan-African Network For Rapid Research, Response, Relief and
Preparedness for Infectious Disease Epidemics (PANDORA-ID-NET)
consortia members, WHO and African Union Member States.
Isolation facilities were identified and the incident management
system (IMS) was activated at various levels. Ports of entry health
staff were crucial for early detection of imported cases given that
Zambia was at risk for importation of COVID-19 (Gilbert et al., 2020).
The University Teaching Hospital (UTH) Virology Biosafety Level-2
(BSL-2) Laboratory, and the University of Zambia School of
Veterinary Medicine BSL-3 Laboratory in Lusaka, Zambia were
identified as national COVID-19 diagnostic testing centres and for
molecular analyses of SARS-CoV-2 lineages. We report the identifi-
cation and clinical management of the first COVID-19 case from
Zambia, and present the phylogenetic analyses of the patient’s SARS-
CoV-2isolate, comparing itwith otherSARS-CoV-2 lineages reported
from other African countries.
Methods
Ethical review and approval to publish
Ethical approval for case study and phylogenomic sequencing,
and publication of this case study was obtained from the University
of Zambia Biomedical Research Ethics Committee (REF. NO. 002-
07-20) and the National Health Research Authority.
Case identification, clinical features and epidemiological investigation
As of 1 February 2020, all travellers arriving at Lusaka Kenneth
Kaunda International Airport in Lusaka, Zambia are screened for
fever in line with the Zambian Ministry of Health COVID-19 public
health response guidelines. On 15 March 2020, a 39-year-old man,
accompanied by his wife and two children, returned to Zambia
from a 2-week trip to Europe (France), the family was placed under
self-quarantine. On 16 March 2020, nasopharyngeal samples
collected by the rapid response team (RRT) for the detection of
the presence of SARS-CoV-2 nucleic acid were positive only in the
case under study. Further questioning indicated that the patient
had a slightly dry and sore throat. On 18 March, 3 days after
returning to Lusaka, our case developed a mild fever (38.0 !C) and
was treated using paracetamol 1 gm three times a day orally for 5
days. Similar to reports from Europe and the USA (Spinato et al.,
2020; Yan et al., 2020a; Yan et al., 2020b), patient had anosmia and
complained of a metallic taste in the mouth 2 days prior to
complete loss of taste. Our patient did not have any co-morbidities
and was placed under quarantine for 21 days after testing positive
to SARS-CoV-2. On day-5 (20th March 2020), he developed a mild
cough, persistent fever (>38 !C), chest discomfort and clinical
examination revealed bilateral chest crepitations. There were
bilateral infiltrates on chest X-ray and full blood count showed
mild lymphopenia (Table 1; Figure 1). He was thus classified as
having ‘moderate COVID-19 pneumonia’ and transferred for
further clinical management at the national COVID-19-specific
hospital where he was isolated, and was given a course of
azithromycin (and then switched to amoxycillin–clavunate acid)
and supportive care. Smell and taste abnormalities resolved within
5 days. The patient did not require intensive care and steadily
improved with resolution of fever and resolution of infiltrates on
repeat chest radiograph. He made a full recovery by day 21.
Repeated contact tracing within the household, showed his wife
testing positive for SARS-CoV-2, but his children remained
negative. There was no further spread to other family members
or attending health care workers.
SARS-CoV-2 detection and molecular sequencing
Specimen collection and RNA extraction
Nasopharyngeal and oropharyngeal swab specimens were
collected on 16 March 2020 in accordance with the CDC
recommendations (CDC, 2020), and samples were processed using
Table 1
Basic metabolic and complete blood count laboratory results.
Test Results on 21 March 2020 Results on 22 March 2020 Result on 29 March 2020
WBC 3.7 " 109/L 5.5 " 109/L
RBC 4.24 " 1012/L 4.46 " 1012/L
Hb 12.5 g/dL 12.9 g/dL
MCV 93 fl 94 fl
Hct 39.3% 41.9%




CREATININE 75.0 mmol/L 84.9 mmol/L
AST 24.4 u/L 29.9 u/L
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standard reverse transcription polymerase chain reaction (RT-PCR)
methodology for SARS-CoV-2 detection.
Whole genome sequencing
For whole genome sequencing, the Sanger method was
employed using several overlapping primers designed using
Geneious software version 10.0.9. The list of primers and their
combinations for RT-PCR assays and sequencing are listed in
Table S1. The complete genome of SARS-CoV-2 investigated in this
study was deposited in GenBank (accession no. MT790522). The
whole SARS-CoV-2 genome generated in this study, together with
other selected SARS-CoV-2 sequences accessed from GISAID
database were aligned using the FFT-NS-2 algorithm available in
the multiple sequence alignment programme (MAFFT) using
default settings. (Katoh et al., 2019) The selection included mostly
representation from all African countries that had deposited whole
genomes in the GISAID database as of 30 August 2020. The
resulting final alignment was then uploaded to the IQ-TREE
webserver (Trifinopoulos et al., 2020) for construction of a
maximum likelihood phylogeny using the general time reversible
nucleotide substitution model and rate of heterogeneity set to
gamma (GTR + G), otherwise default settings. Branch robustness
was estimated using ultrafast bootstrapping tool available in IQ-
TREE with 1000 replicates (Minh et al., 2013). The ML tree was then
rooted using TempEst (version 1.5.1) (Rambaut et al., 2016), which
estimated the best-fitting root of this phylogeny using the heuristic
residual mean squared function, aimed at minimizing the variance
of root-to-tip distances. The resultant ML tree file was edited using
iTOL (Letunic and Bork, 2019). Viral lineages were identified in the
phylogeny according to the recently described nomenclature
(Rambaut et al., 2020) as well as demonstrated recently in Uganda
(Bugembe et al., 2020).
Results
Phylogenetic and sequence analysis
Phylogenomic analysis showed that the detected SARS-CoV-2
belonged to lineage B.1.1, sharing the most common recent
ancestor with viruses detected in South Africa (Figure 2). At the
African continental level, our analysis showed that lineage B.1.1
was detected in many countries in Africa, including Nigeria,
Morocco, Gambia, Ghana, Senegal, Kenya and South Africa. Outside
Africa, this monophyletic group comprised strains from France,
Spain and Argentina. While our phylogenomic tree clearly showed
that all the known SARS-CoV-2 lineages are present in Africa,
lineages B.1 and B.1.1 were seemingly dominating the continent.
When compared with Wuhan-Hu-1 (accession no. MN908947),
the SARS-CoV-2 investigated in this study showed nine nucleotide
differences: C241 T, C3037 T, C3796 T, T11725C, C14408 T, A23403
G, G28881A, G28882A and G28883C. Four amino acid differences
were observed: P4715 L (orf1ab polyprotein), D614 G (surface
glycoprotein), R203 K and G204R in the nucleocapsid phospho-
protein.
Discussion
While it was not possible to establish where our first Zambia
COVID-19 patient contracted the infection while traveling in
Europe or in transit, phylogenomic analysis placed the Zambian
SARS-CoV-2 into lineage B.1.1 (Figure 2), a lineage that has spread
to various countries in Europe, South America, Asia, Oceania and
Africa (https://github.com/cov-lineages/lineages). The close clus-
tering of the Zambian virus with SARS-CoV-2 sequences from
South Africa (Figure 2) may imply a common origin of B.1.1 lineage
in southern Africa. Our phylogenomic comparisons of SARS-CoV-2
detected in African countries revealed the presence of all the major
lineages that have been found globally. This implies that some
African countries may have delayed in banning international
flights from other high-risk continents and closing of borders with
neighbouring countries. As such, many countries in Africa
remained vulnerable to importation of several SARS-CoV-2
lineages, which compounds tracking of virus transmission chains
and pandemic control efforts. Limiting multiple introductions of
imported cases and prudent management of identified cases at
local or regional level through efficient community testing, contact
tracing and quarantine measures are key considerations for
present and future responses to pandemic threats. Zambia had
put in place an alert surveillance system that was able to identify
the initial cases very quickly.
The B.1.1 lineage has been defined by 28881GA, 28882GC and
28883GC single-nucleotide polymorphisms (SNPs), but our strain
showed some variation by having 28882GA. Analysis of the
genome of the Zambia virus revealed only four amino acid
differences when compared with Wuhan-Hu-1, which included
the D614 G mutation which has been observed to correlate with
increased case fatality rates (Becerra-Flores and Cardozo, 2020).
The SARS-CoV-2 reported in this study also had the P4715 L
mutation which has been observed to occur in almost all strains
with D614 G mutation, which might affect the speed of virus
replication (Koyama et al., 2020). SARS-CoV-2 variants with P4715
L predominate in Europe and the USA (Koyama et al., 2020). While
most (if not all) of the complete genomes of SARS-CoV-2 deposited
in public databases were sequenced using next generation
sequencing (NGS) platforms, we utilized the Sanger method,
which is more widely available in Africa when compared with NGS.
As laboratory capacities for NGS are yet to be developed in many
African countries, the Sanger method could still be used to
sequence a number of complete genomes enough to provide a
better understanding of the molecular epidemiology of SARS-CoV-
2 in Zambia.
The epidemic preparedness and response in Zambia remains on
high alert for the COVID-19 pandemic and capacity for contact
tracing in the community has been built steadily over time due to
experience with previous outbreaks such as Lujo haemorrhagic
Figure 1. Chest X-ray (CXR) of the first case of COVID-19 in Zambia. The CXR was
taken on day 4 after the onset of illness. White arrow shows nodular infiltrates
suspected to be micro-abscesses.
Black arrows show bilateral infiltrates affecting lower zones mostly peripheral and
the centre.
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fever and cholera (Paweska et al., 2009; Kapata et al., 2018) as well
as ongoing surveillance for influenza and haemorrhagic fever
viruses in humans and animals including wildlife (Simulundu
et al., 2011; Ogawa et al., 2015; Theo et al., 2012; Changula et al.,
2018; Kajihara et al., 2019; Simusika et al., 2020). These activities
have contributed to capacity building for the various multi-
disciplinary teams working in the health facilities including
laboratories for infectious diseases and public health emergencies..
Health system strengthening for future outbreaks using the ‘One
Health’ multisectoral approach has also proved to be a key
ingredient to mounting an effective response towards prevention
of spread of COVID-19. The COVID-19 outbreak, though originally
from China, was detected in Zambia as a result of intercontinental
spread largely facilitated by international travel, demonstrating
the role of globalization in aiding SARS-CoV-2 transmission across
international borders including in Africa (Bugembe et al., 2020).
Genotypic analysis of SARS-CoV-2 from all Asia, Europe and
Americas shows that the genes encoding the S proteins and RNA
polymerase, RNA primase and nucleoprotein, undergo frequent
mutations which are important for vaccine development in disease
control. Discriminating and comparative analyses of vSARS-CoV-2
isolates can be useful in genetic epidemiology. An understanding of
the different genotypes of SARS-CoV-2 strains that are circulating
in Zambia and in the Central African region may have implications
for vaccine development, transmission and virulence
Conclusion
We report the case history and phylogenomic analyses of SARS-
CoV-2 for the first COVID-19 case detected in Zambia. The case
history and molecular epidemiology data do not rule out the
possibility of direct or indirect importation of the virus from
Europe. Phylogenomic analysis showed that the detected SARS-
CoV-2 belonged to lineage B.1.1 sharing the most common recent
ancestor with SARS-CoV-2 strains recovered from South Africa. At
the African continental level, our analysis showed that B.1 and B.1.1
lineages appear to be predominant in Africa. Whole genome
sequence analysis should be part of all surveillance activities to
monitor the origin and evolution of SARS-CoV-2 lineages across
Africa.
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Figure 2. A maximum likelihood tree showing phylogenetic relationships of the complete genome of SARS-CoV-2 detected in a patient in Zambia and other 73 SARS-CoV-2
genomes retrieved from the GISAID database. Of the 73 genomes, 59 were a selection representing African countries that had deposited whole genomes in the GISAID
database. The genome generated in this study is shown in red. Viral lineages are shown as shaded areas. The scale shows nucleotide substitutions per site (see attached file for
clearer image).
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